Urelumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Urelumab
Accession Number
DB12077  (DB05960)
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
BMS 663513 / BMS-663513 / BMS-66513
Categories
Not Available
UNII
230902QLLC
CAS number
934823-49-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 9Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911279
Wikipedia
Urelumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentMelanoma (Skin) / Skin Cancers1
1Active Not RecruitingTreatmentNeoplasms Malignant1
1CompletedTreatmentB-Cell Malignancies1
1CompletedTreatmentCancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma1
1CompletedTreatmentColorectal Cancers / Head and Neck Carcinoma1
1CompletedTreatmentMultiple Myeloma (MM)1
1RecruitingTreatmentGlioblastomas / Gliosarcoma / Recurrent Brain Neoplasm1
1RecruitingTreatmentMalignancies1
1TerminatedTreatmentAdvanced Solid Malignancies1
1TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentMelanoma1
1, 2CompletedTreatmentAdvanced B-cell NHL / Advanced Solid Tumors1
1, 2Not Yet RecruitingTreatmentNeoplasms1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentTumors1
2WithdrawnTreatmentLeukemias1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Tumor necrosis factor-activated receptor activity
Specific Function
Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
Gene Name
TNFRSF9
Uniprot ID
Q07011
Uniprot Name
Tumor necrosis factor receptor superfamily member 9
Molecular Weight
27898.6 Da

Drug created on October 20, 2016 15:18 / Updated on June 04, 2019 07:31